Gold bars to be exempt from tariffs, White House clarifies
NEW YORK - Psyence Biomedical Ltd. (NASDAQ:PBM), a micro-cap biotech company with a market capitalization of $3.15 million, announced Thursday that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract that meets all microbial safety standards for food-grade consumption. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 11.04.
The high-purity extract was verified by an accredited third-party laboratory, according to the company’s press release. Psyence BioMed acquired an equity stake in PsyLabs in 2024 and continued its investment in 2025. The company’s stock, trading at $5.40, has experienced significant volatility this year, with a year-to-date return of -67.89%.
"This is a groundbreaking moment for our entire team on the ground who have put countless hours and effort into ensuring our naturally derived, sustainable input materials are extracted with the same caution, mindfulness, and care," said Cody Robyn Futeran, Head of Extraction Innovations and Business Development at PsyLabs.
PsyLabs is currently expanding its chemistry production area to meet growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity products derived from both Iboga and mushrooms.
Tony Budden, CEO of PsyLabs, stated that the company is "committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs."
According to the announcement, PsyLabs’ Ibogaine will be available to licensed research institutions and developers worldwide. The company operates from an ISO 22000-certified facility audited by the British Standards Institution.
Psyence Biomedical describes itself as a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on developing nature-derived psilocybin and ibogaine-based psychedelic medicine. With a price-to-book ratio of 0.47, InvestingPro analysis suggests the stock may be undervalued. Discover more detailed financial metrics and exclusive insights with an InvestingPro subscription, including over 30 additional ProTips for PBM.
The information in this article is based on a press release statement from Psyence Biomedical Ltd.
In other recent news, Psyence Biomedical has regained compliance with Nasdaq’s continued listing requirements after implementing a reverse stock split. The company executed a 1-for-7.97 reverse stock split to meet Nasdaq’s minimum bid price requirement, following shareholder approval for a potential split ratio of up to 1-for-50. This corporate action reduced the number of issued and outstanding common shares from approximately 4.65 million to 583,263. Additionally, Psyence Biomedical has advanced its Phase IIb psilocybin trial through a new partnership with Southern Star Research, an Australian Contract Research Organization. Southern Star Research will manage clinical monitoring, project management, and data handling for the trial in Australia. This collaboration is expected to enhance the trial’s quality and regulatory compliance. The trial focuses on psilocybin-assisted psychotherapy for cancer patients with Adjustment Disorder. These developments reflect Psyence Biomedical’s ongoing efforts to strengthen its market position and advance its clinical research initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.